Överenskommelser har nåtts med majoriteten av obligationsinvesterarna.
Redeye comments on Amniotics' H1 report 2024, which will likely be its last before the merger with M...
Redeye concludes that the reported figures were overall stronger than we had forecasted.
Redeye sees the Q2 report coming in below estimates for both sales and EBIT.
Redeye sees a quarter demonstrating continued strong sales growth and an OPEX that is in line with o...
Taaleri reported Q2 EBIT of EUR 4.4m, clearly above LSEG Data & Analytics consensus at EUR 3.
Transfer Group visade stark tillväxt under det andra kvartalet, med en nettoomsättning på cirka 51 (...
Redeye updates on GiG ahead of Q2-results (due 28 August) where we expect continued stable performan...
On 19 August 2024, Føroya Banki raised its 2024 net profit guidance range to DKK 250-280m (previousl...
Solid sequential improvements, first Ovzon 3 order '24e-'26e sales down 18-7% on softer orders than ...
Q2e: EMS industry under pressure; Inission should fare relatively well '24 sales target challenging ...
USA more stable, but poor result in Germany Negative EBIT revisions primarily driven by Germany Trad...
Administer’s Q2 EBITDA soared by 320% y/y, reaching EUR 1.
Despite Pampalo’s profitability not meeting our expectations in H1, we anticipate substantial volume...
Endomines' net sales for the first half of the year were roughly as expected, though profitability d...
